Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review

M. R. Tramer¹* and T. Fuchs-Buder²

¹Division of Anaesthesiology, Department APSIC, Geneva University Hospital, CH-1211 Geneva 14, Switzerland. ²Department of Anaesthesiology, University of Saarland, D-66421 Homburg/Saar, Germany

*To whom correspondence should be addressed

We have estimated the effect of omitting antagonism of neuromuscular block on postoperative nausea and vomiting. A systematic search (MEDLINE, EMBASE, Biological Abstracts, Cochrane library, reference lists and hand searching; no language restriction, up to March 1998) was performed for relevant randomized controlled trials. In eight studies (1134 patients), antagonism with neostigmine or edrophonium was compared with spontaneous recovery after general anaesthesia with pancuronium, vecuronium, mivacurium or tubocurarine. On combining neostigmine data, there was no evidence of an antiemetic effect when it was omitted. However, the highest incidence of emesis with neostigmine 1.5 mg was lower than the lowest incidence of emesis with 2.5 mg. Numbers-needed-to-treat to prevent emesis by omitting neostigmine compared with using it were consistently negative with 1.5 mg, and consistently positive (3–6) with 2.5 mg. There was a lack of evidence for edrophonium. In two studies, three patients with spontaneous recovery after mivacurium or vecuronium needed rescue anticholinesterase drugs because of clinically relevant muscle weakness (number-needed-to-harm, 30). Omitting neostigmine may have a clinically relevant antiemetic effect when high doses are used. Omitting antagonism, however, introduces a non-negligent risk of residual paralysis even with short-acting neuromuscular blocking agents.

Keywords: vomiting, nausea; vomiting, incidence; antagonists neuromuscular block, neostigmine; antagonists neuromuscular block, edrophonium; neuromuscular block, antagonism; anaesthesia, audit

Accepted for publication: October 19, 1998

It has been suggested that antagonism of residual neuromuscular block with a mixture of neostigmine and atropine at the end of surgery increases the risk of postoperative nausea and vomiting (PONV).¹ As a consequence, omitting antagonism of neuromuscular block would decrease the incidence of PONV. However, results from randomized controlled trials (RCT) are contradictory. In one trial, omitting neostigmine at the end of surgery had a statistically significant beneficial effect on PONV.² In another, neostigmine did not influence the risk of PONV.³ Authors of yet another study suggested that neostigmine may actually have antiemetic properties.⁴

The aim of this quantitative systematic review was to test the evidence that antagonism of neuromuscular block at the end of surgery influences the incidence of PONV, and to evaluate the likelihood of harm when antagonism was omitted.

Methods

Inclusion criteria

We included published full reports of RCT which investigated the effect of spontaneous recovery of neuromuscular block (i.e. antagonism was omitted, experimental group) compared with the same anaesthetic but with active antagonism of neuromuscular block with anticholinesterase drugs (control group). Spontaneous recovery of neuromuscular block was assumed when patients received a placebo or no treatment. Relevant trials had to report dichotomous data (presence or absence of an event) on PONV or adverse events.

Systematic search and validity score

We searched systematically for relevant reports in MEDLINE (from 1966), Biological Abstracts (from 1966),
EMBASE (from 1980) and Cochrane Library (1998, issue 1) (date of last electronic search March 20, 1998). The searches were with combinations of the free text terms ‘nausea, vomiting, emesis, neostigmine, prostigmine, edrophonium, antagonism and neuromuscular block’. Reference lists of retrieved reports and review articles were checked. Locally available anaesthesia journals were hand-searched. The search was not restricted to the English language. Abstracts were not considered. Authors were contacted by letter when there was ambiguity about data. Each retrieved report was read by both authors independently to assess adequacy of randomization and blinding, and description of withdrawals using the validated three-item, 5-point Oxford score. Reports which were described as ‘randomized’ were given 1 point, and another point if the method of randomization was described and adequate (such as a table of random numbers). Randomization was assumed when stated as such in the report. One point was given when the study was described as ‘double-blind’. When the method of double-blinding was described and adequate (identical ampoules, for instance), another point was given. Finally, reports which described the number and reasons for withdrawals were given 1 point. Thus the maximum score of an included randomized controlled trial was 5 and the minimum score was 1. We compared the allocated scores and resolved differences by discussion.

Data extraction

We obtained information on patients, anaesthetic, type and dose of anticholinesterase drugs, controls, surgery, study end-points and intervention-related adverse effects from each included report. Only dichotomous data on efficacy and harm were extracted. Relevant efficacy data were prevention of early emetic events (cumulative incidence nearest to 6 h after surgery) and prevention of late emetic events (cumulative incidence nearest to 48 h). A maximum of three different emetic events were extracted from each trial, for both early and late: nausea, vomiting (including retching) and any emetic event (nausea, vomiting, or nausea and vomiting). Events were treated separately.

Dichotomous data on clinically diagnosed adverse events related to omitting antagonism were extracted as described in the original reports. Clinically overt muscle weakness was such an end-point. Data on neuromuscular monitoring (train-of-four ratio, for instance) were not considered.

Quantitative analysis (meta-analysis)

For individual and combined trials, the relative antiemetic benefit of omitting antagonism was calculated as relative risk with 95% confidence intervals (CI). A random effects model was used to combine data. The random effects model incorporates both within- and between-study variance, and yields a more conservative estimate of treatment effect when there is variability in results. A statistically significant difference between intervention (omitting antagonism) and control (giving an anticholinesterase drug) was assumed when the 95% confidence interval of the relative risk did not include 1.

Numbers-needed-to-treat were calculated. We decided to calculate 95% CI around the number-needed-to-treat point estimate only when the relative risk indicated a statistically significant difference between intervention and control (because then the confidence interval around the number-needed-to-treat would not include infinity). A positive number-needed-to-treat indicated how many patients had to be exposed to the intervention (i.e. omitting antagonism) in order to prevent one particular emetic event in one patient, who would have had this event had they received an anticholinesterase drug. Thus a positive number-needed-to-treat indicated that omitting anticholinesterase drugs had an antiemetic effect and, therefore, antagonism was emetogenic. According to pre-set criteria, a number-needed-to-treat between 1 and 5 was considered as a clinically relevant improvement. A negative number-needed-to-treat indicated less risk of PONV with pharmacological antagonism compared with spontaneous recovery, suggesting that anticholinesterase drugs had an antiemetic effect.

For estimation of the additional risk of intervention-related adverse effects, we calculated relative risk with 95% CI and the number-needed-to-harm, as for number-needed-to-treat. If any cell of a sample was zero, then 0.5 was added to all cells of that sample to calculate the relative risk. Calculations were performed using Excel 5.0 on a Power Macintosh G3.

Results

Retrieved reports

Eleven reports were found. Three were subsequently excluded; two had neither a placebo nor a no-treatment group. The third trial did not report any data on PONV or intervention-related harm, and the original authors were not able to respond to our enquiry to provide relevant data.

Analysed reports

Eight trials with data on 1134 patients were analysed (Table 1). One trial with a pseudo-randomization (alternans allocation) was included in the analysis. The median quality score of the RCT was 3 (range 1–4). Mean study size was 142 patients (range 38–464).

Different doses of edrophonium or neostigmine combined with different doses of atropine or glycopyrrolate were compared with placebo or no treatment in children and adults. Neuromuscular blocking agents were pancuronium, tubocurarine, vecuronium and mivacurium. Seven trials reported valid PONV data. Observation periods were during patient stay in the post-anaesthetic care unit (PACU) and up to a maximum of 27 h after surgery. One trial did not report PONV data but reported muscle weakness in patients who did not receive anticholinesterase drugs. This trial was included in the analysis of intervention-related harm.
### Table 1: Antagonism of neuromuscular block in the analysed trials (n = nausea; v = vomiting; n+v = any event; PACU = post-anaesthetic care unit)

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Score</th>
<th>Setting (Ad = adults; Paed = children)</th>
<th>Patients analysed</th>
<th>Anaesthetic</th>
<th>Neuramuscualr blocking agent (I = Induction; M = Maintenance; () = group)</th>
<th>Intervention thought to be emetogenic</th>
<th>Control</th>
<th>Follow-up</th>
<th>Def. PONV</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>[12]</td>
<td>2 2 0</td>
<td>Different surgeries Ad and Paed</td>
<td>100</td>
<td>Propofol, N(_2)O, fentanyl</td>
<td>I: mivacurium M: mivacurium infusion</td>
<td>Edrophonium 50 µg kg(^{-1}) + atropine 20 µg kg(^{-1})</td>
<td>Placebo</td>
<td>PACU</td>
<td>n/a</td>
<td>No PONV data. Two placebo patients needed edrophonium to restore ventilation and muscle power.</td>
</tr>
<tr>
<td>[4]</td>
<td>1 0 1</td>
<td>Different surgeries Ad</td>
<td>79</td>
<td>Thiopental, halothane–N(_2)O, fentanyl</td>
<td>I: vecuronium 0.1 mg kg(^{-1}) 1/2 (3): mivacurium 0.2 mg kg(^{-1}) M(2+3): mivacurium boluses 2.4 mg</td>
<td>Neostigmine 1.5 mg + atropine 0.5 mg</td>
<td>No treatment</td>
<td>Day case</td>
<td>n v</td>
<td>Blinded observer. Atropine 0.5 mg i.v. at induction in all patients. One control patient needed reversal and was excluded from analysis.</td>
</tr>
<tr>
<td>[2]</td>
<td>1 0 0</td>
<td>Gynaecology laparoscopy</td>
<td>60</td>
<td>Midazolam, thiopental, fentanyl, isoflurane–N(_2)O</td>
<td>I(1): succinylcholine 1 mg kg(^{-1}) 1/2 (3): mivacurium 0.2 mg kg(^{-1}) 0.2 mg kg(^{-1})</td>
<td>Neostigmine 2.5 mg + glycopyrrolate 0.5 mg</td>
<td>(1+2): no treatment</td>
<td>PACU</td>
<td>n v</td>
<td>Late outcomes not cumulative. Observer not blinded. Group 1 considered as no treatment control.</td>
</tr>
<tr>
<td>[3]</td>
<td>1 2 1</td>
<td>Abdominal hysterectomy</td>
<td>160</td>
<td>Thiopental, fentanyl, isoflurane–N(_2)O</td>
<td>I: mivacurium 0.2 mg kg(^{-1}) M: mivacurium infusion (TOF 1–2 twitches)</td>
<td>Neostigmine 2.0 mg + glycopyrrolate 0.4 mg</td>
<td>Placebo</td>
<td>PACU</td>
<td>n v</td>
<td>Prophylactic glycopyrrolate 0.2 mg in all patients.</td>
</tr>
<tr>
<td>[16]</td>
<td>0 0 0</td>
<td>Cholecystectomy Venous stripping</td>
<td>464</td>
<td>Thiopental, pethidine, N(_2)O or halothane</td>
<td>I: succinylcholine 1 mg kg(^{-1}) 0.5 mg kg(^{-1})</td>
<td>Neostigmine 2.0 mg + atropine 1 mg</td>
<td>No treatment</td>
<td>24 h</td>
<td>n v</td>
<td>Pseudo-randomization (alternans). Combined 'standard' and 'halothane' groups considered as control.</td>
</tr>
<tr>
<td>[17]</td>
<td>1 0 0</td>
<td>Orthopaedics Ad</td>
<td>38</td>
<td>Methohexital, halothane–N(_2)O, morphine</td>
<td>I: succinylcholine 1 mg kg(^{-1}) 0.5 mg kg(^{-1})</td>
<td>Neostigmine 2.5 mg + atropine 1.2 mg</td>
<td>No treatment</td>
<td>24 h</td>
<td>n v</td>
<td></td>
</tr>
<tr>
<td>[18]</td>
<td>2 0 1</td>
<td>Strabismus Paed</td>
<td>120</td>
<td>Thiopental, atropine, halothane–N(_2)O</td>
<td>I: succinylcholine 1.5 mg kg(^{-1}) M: pancuronium 0.05 mg kg(^{-1})</td>
<td>Neostigmine 60 µg kg(^{-1}) + atropine 20 µg kg(^{-1})</td>
<td>No treatment</td>
<td>2 h</td>
<td>v</td>
<td>Considered as controlled study despite differences in ventilation and curare.</td>
</tr>
<tr>
<td>[19]</td>
<td>1 2 0</td>
<td>Different minor surgeries Paed</td>
<td>113</td>
<td>Halothane–N(_2)O, fentanyl intra-, morphine postoperatively</td>
<td>I: mivacurium 0.2 mg kg(^{-1}) M: mivacurium infusion (TOF 1 twitch)</td>
<td>Neostigmine 70 µg kg(^{-1}) + glycopyrrolate 10 µg kg(^{-1}) 1: edrophonium 1 mg kg(^{-1})</td>
<td>Placebo active</td>
<td>PACU</td>
<td>24 h v</td>
<td>Emesis considered as vomiting.</td>
</tr>
</tbody>
</table>
Table 2  Efficacy of omitting antagonism of neuromuscular block: neostigmine. EER = Experimental event rate (incidence of PONV when antagonism of neuromuscular block is omitted); CER = Control event rate (incidence of PONV with antagonism of neuromuscular block)

<table>
<thead>
<tr>
<th>Dose of neostigmine</th>
<th>No. of patients with outcome/total number of patients</th>
<th>EER (%)</th>
<th>Antagonism CER (%)</th>
<th>Relative risk (95% CI)</th>
<th>Number-needed-to-treat</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of early nausea (0–6 h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 mg</td>
<td>23/39</td>
<td>41.0</td>
<td>29/40</td>
<td>27.5</td>
<td></td>
<td>[4]</td>
</tr>
<tr>
<td>2.0 mg</td>
<td>69/80</td>
<td>13.8</td>
<td>69/80</td>
<td>13.8</td>
<td></td>
<td>[3]</td>
</tr>
<tr>
<td>2.5 mg</td>
<td>27/40</td>
<td>32.5</td>
<td>7/20</td>
<td>65.0</td>
<td></td>
<td>[2]</td>
</tr>
<tr>
<td>Combined</td>
<td>119/159</td>
<td>25.2</td>
<td>105/140</td>
<td>25.0</td>
<td>1.04 (0.76–1.43)</td>
<td>–636</td>
</tr>
<tr>
<td>Prevention of early vomiting (0–6 h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 mg</td>
<td>28/39</td>
<td>28.2</td>
<td>34/40</td>
<td>15.0</td>
<td></td>
<td>[4]</td>
</tr>
<tr>
<td>2.0 mg</td>
<td>71/80</td>
<td>11.3</td>
<td>71/80</td>
<td>11.3</td>
<td></td>
<td>[3]</td>
</tr>
<tr>
<td>2.5 mg</td>
<td>29/40</td>
<td>27.5</td>
<td>11/20</td>
<td>45.0</td>
<td></td>
<td>[2]</td>
</tr>
<tr>
<td>60 µg kg⁻¹</td>
<td>30/60</td>
<td>50.0</td>
<td>36/60</td>
<td>40.0</td>
<td></td>
<td>[18]</td>
</tr>
<tr>
<td>70 µg kg⁻¹</td>
<td>33/37</td>
<td>10.8</td>
<td>25/38</td>
<td>34.2</td>
<td></td>
<td>[19]</td>
</tr>
<tr>
<td>Combined</td>
<td>191/256</td>
<td>25.4</td>
<td>177/238</td>
<td>25.6</td>
<td>1.03 (0.86–1.22)</td>
<td>417</td>
</tr>
<tr>
<td>Prevention of late nausea (0–27 h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 mg</td>
<td>23/39</td>
<td>41.0</td>
<td>26/40</td>
<td>35.0</td>
<td></td>
<td>[4]</td>
</tr>
<tr>
<td>2.0 mg</td>
<td>57/80</td>
<td>28.8</td>
<td>52/80</td>
<td>35.0</td>
<td></td>
<td>[3]</td>
</tr>
<tr>
<td>2.5 mg</td>
<td>13/19</td>
<td>31.6</td>
<td>6/19</td>
<td>68.4</td>
<td></td>
<td>[17]</td>
</tr>
<tr>
<td>Combined</td>
<td>93/138</td>
<td>32.6</td>
<td>84/139</td>
<td>39.6</td>
<td>1.11 (0.93–1.33)</td>
<td>14</td>
</tr>
<tr>
<td>Prevention of late vomiting (0–27 h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 mg</td>
<td>25/39</td>
<td>35.9</td>
<td>32/40</td>
<td>20.0</td>
<td></td>
<td>[4]</td>
</tr>
<tr>
<td>2.0 mg</td>
<td>48/80</td>
<td>40.0</td>
<td>54/80</td>
<td>32.5</td>
<td></td>
<td>[3]</td>
</tr>
<tr>
<td>2.0 mg</td>
<td>23/82</td>
<td>72.0</td>
<td>154/382</td>
<td>59.7</td>
<td></td>
<td>[16]</td>
</tr>
<tr>
<td>2.5 mg</td>
<td>17/19</td>
<td>10.5</td>
<td>10/19</td>
<td>47.4</td>
<td></td>
<td>[17]</td>
</tr>
<tr>
<td>70 µg kg⁻¹</td>
<td>21/37</td>
<td>43.2</td>
<td>17/38</td>
<td>55.3</td>
<td></td>
<td>[19]</td>
</tr>
<tr>
<td>Combined</td>
<td>134/257</td>
<td>47.9</td>
<td>267/559</td>
<td>52.2</td>
<td>0.98 (0.75–1.28)</td>
<td>23</td>
</tr>
</tbody>
</table>

Antiemetic efficacy of omitting antagonism of neuromuscular block

Neostigmine—efficacy data
Neostigmine 60 or 70 µg kg⁻¹, and 1.5, 2.0 or 2.5 mg was used in seven trials. When emetic outcomes were combined (i.e. nausea or vomiting separately, both early and late) across all trials and all neostigmine doses, there was neither a statistically significant nor a clinically relevant effect of omitting neostigmine on PONV (Table 2). For all outcomes, 95% CI of the relative risk included 1, and numbers-needed-to-treat were negative or greater than 10.

Absolute risk of PONV with placebo or no treatment, and with neostigmine
Five trials compared three different fixed doses of neostigmine (i.e. 1.5, 2.0 and 2.5 mg) with placebo or no treatment.²⁻⁴ ¹⁶ ¹⁷ In patients receiving placebo or no treatment, and thus exposed to spontaneous recovery, the absolute risk (incidence) of early nausea and vomiting was 10–40%, and of late nausea and vomiting, 10–70% (Fig. 1). Corresponding values in patients receiving neostigmine 1.5 mg (one trial), 2.0 mg (two trials) or 2.5 mg (two trials) suggested an increased risk of PONV with increasing dose of neostigmine. For both early and late outcomes, the highest incidence of PONV with the lowest dose tested (1.5 mg) did not overlap with the lowest incidence of PONV with the highest dose of neostigmine tested (2.5 mg) (Fig. 1).

Number-needed-to-treat to prevent PONV by omitting neostigmine
In one trial, the lowest dose of neostigmine (1.5 mg) was compared with no treatment in 79 patients.² For all outcomes (i.e. nausea and vomiting, both early and late) numbers-needed-to-treat were negative (Fig. 2), suggesting an antiemetic effect with neostigmine. Two of four results were statistically significant.

Fig 1  Cumulative incidence of early and late nausea and vomiting with placebo and three different doses of neostigmine in five trials. Symbol size does not take into account trial size.

PONV with the highest dose of neostigmine tested (2.5 mg) (Fig. 1).

Fig 2  Cumulative incidence of early and late nausea and vomiting with placebo and three different doses of neostigmine in five trials. Symbol size does not take into account trial size.
Two trials compared the medium dose of neostigmine (2.0 mg) with placebo or no treatment in 624 patients (Fig. 2). Results were inconsistent. The numbers-needed-to-treat to prevent PONV by omitting neostigmine 2.0 mg ranged from approximately 15 (suggesting an emetogenic effect when using neostigmine, albeit clinically not relevant) to negative values (suggesting an antiemetic effect when using neostigmine). Two of five results were statistically significant.

In two trials, the highest dose of neostigmine tested (2.5 mg) was compared with no treatment in 98 patients (Fig. 2). For all outcomes the numbers-needed-to-treat were positive (3–6), suggesting a clinically relevant emetogenic effect of neostigmine, that is an antiemetic effect when neostigmine at this dose was omitted. Three of four results were statistically significant.

Two trials compared body weight-adjusted doses of neostigmine in 233 children. In one trial, the incidence of vomiting in children receiving neostigmine 60 µg kg\(^{-1}\) was lower compared with children not receiving it. Accordingly, the number-needed-to-treat to prevent vomiting was negative but the result was not statistically significant (relative risk 0.83 (0.60–1.16)). In the other trial, a larger dose of neostigmine (70 µg kg\(^{-1}\)) was compared with placebo. The numbers-needed-to-treat when antagonism was omitted were 4.3 (2.4–19), relative risk 1.36 (1.05–1.75) for early outcomes, and 8.3, relative risk 1.27 (0.81–1.99) for late outcomes. These data suggested a clinically relevant emetogenic effect with the higher dose of neostigmine in the immediate postoperative period but not thereafter.

Edrophonium—efficacy data

One trial investigated the effect of omitting edrophonium 1 mg kg\(^{-1}\) on PONV in 38 children and reported PONV data. Omitting edrophonium had no beneficial effect on early emesis (relative risk 1.09 (0.91–1.32), number-needed-to-treat 13), or on late emesis (relative risk 1.27 (0.81–1.99), number-needed-to-treat 8).

Harm related to omitting antagonism of neuromuscular block

Two trials reported clinically relevant muscle weakness in the immediate postoperative period in three of 90 patients who had received placebo but in none of 90 patients who had received edrophonium or neostigmine (Table 3). All three patients needed rescue anticholinesterase drugs to restore ventilation and muscle power. In one of these trials, surgical paralysis was achieved with a single dose of vecuronium 0.1 mg kg\(^{-1}\) at induction. In the other trial, mivacurium 0.2 mg kg\(^{-1}\) was used to facilitate intubation and a mivacurium infusion during surgery was set to achieve a train-of-four response of 1–2 twitches. The other trials did not report presence or absence of such adverse events.

Based on data from these two trials, the number-needed-to-harm point estimate to produce one patient with clinically relevant muscle weakness by omitting neostigmine or edrophonium compared with giving these drugs was 13 (Table 3).

Discussion

In theory, different mechanisms could be responsible for an increased risk of PONV with the use of anticholinesterase drugs. For instance, a combination of atropine and neostigmine was shown to decrease lower oesophageal sphincter pressure in men. Also, anticholinesterase drugs have antimuscarinic effects on the gastrointestinal tract which increase motility and stimulate secretion of gastric fluid and acid. Because these effects are partly prevented by anticholinergic drugs, such as atropine, it was suggested that omitting antagonism of neuromuscular block decreases the risk of PONV because anticholinergic drugs are given concomitantly with antagonism. Finally, in healthy volunteers, intrathecal neostigmine caused severe nausea and vomiting in a dose-dependent manner. These authors suggested that the most likely site of this adverse effect was in the brainstem. A similar, dose-dependent emetogenic effect with intrathecal neostigmine was found in women undergoing Caesarean section. The relevance of this, when anticholinesterase drugs are administered systemically, is not known.

Our aim was to test the evidence that antagonism of neuromuscular block at the end of surgery influences the incidence of PONV, and to evaluate the likelihood of harm when antagonism was omitted. However, only a limited number of patients have been tested in these systematically searched trials. Therefore, caution must be exercised in interpreting the results. For instance, it may not be justifiable to attempt dose–response relationships with such a small number of patients.

There is widespread belief that anticholinergic drugs (atropine, glycopyrrolate), which are regularly administered together with anticholinesterase drugs, decrease the risk of PONV. However, there is no substantial evidence to support this view. In RCT, no difference in the incidence of PONV has been shown with atropine or glycopyrrolate compared
with placebo. Therefore, whatever limitations caused by the small numbers in these systematically searched controlled trials, we have to assume that any observed effect is most likely due to the absence or presence of anticholinesterase drugs.

There was some evidence that in adults, antagonism of postoperative neuromuscular block with the highest dose of neostigmine (2.5 mg) may increase the risk of PONV. In two RCTs with almost 100 patients, omitting this high dose of neostigmine at the end of surgery had a consistent, statistically significant antiemetic effect. The combined data suggest that 1 in 3–6 patients exposed to spontaneous recovery of neuromuscular block will not suffer PONV symptoms who would have done so had they received neostigmine 2.5 mg, a degree of benefit which may be regarded as clinically relevant. Lower doses of neostigmine either gave inconsistent results (2.0 mg) or even suggested an antiemetic effect (1.5 mg). In addition, the lowest reported incidence of PONV with the highest dose of neostigmine tested in these trials (2.5 mg) did not overlap with the highest incidence of PONV with the lowest dose of neostigmine (1.5 mg). The synthesis of these, although sparse, data may be regarded as evidence of dose-responsiveness. This could explain the confusion about antagonism of neuromuscular block and PONV.

Clinical implications

Benefit vs harm

These efficacy data need to be put into a clinical context. For instance, the benefit of a particular intervention has to be balanced against its potential for harm. Thus the antiemetic benefit when omitting pharmacological antagonism of neuromuscular block has to be weighed against the risk of residual muscle paralysis because antagonism was omitted.

PONV is distressing and interferes with patient comfort, but it never becomes chronic and is almost never life-threatening. Here, the limiting factor in decision making is likely to be the additional risk caused by muscle paralysis when antagonism is omitted. The main questions are: What is the incidence of residual paralysis?

What is the clinical relevance of residual paralysis?

Muscle weakness may lead to hypoventilation with subsequent hypercapnia and hypoxia. Residual paralysis may attenuate the ventilatory response to hypoxia, impairing adequate function of the carotid body. Residual paralysis impairs coughing, increasing the likelihood of atelectasis. In addition, compromised laryngeal and pharyngeal function could lead to upper airway obstruction or aspiration. Because residual paralysis reduces the safety margin, spontaneously breathing patients are more vulnerable to specific drug interactions in the immediate postoperative period.

Table 3 Insufficient muscle power on awakening requiring rescue antagonism

<table>
<thead>
<tr>
<th>Neur muscular blocking agent</th>
<th>Placebo or no treatment</th>
<th>Antagonism</th>
<th>Relative risk (95% CI)</th>
<th>Number-needed-to-Harm</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mivacurium</td>
<td>2/50</td>
<td>0/50</td>
<td>4.00 (0.46–35.1)</td>
<td>30</td>
<td>[12]</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>1/40</td>
<td>0/40</td>
<td>4.00 (0.46–35.1)</td>
<td>30</td>
<td>[4]</td>
</tr>
<tr>
<td>Combined</td>
<td>3/90</td>
<td>0/90</td>
<td>4.00 (0.46–35.1)</td>
<td>30</td>
<td>[4,12]</td>
</tr>
</tbody>
</table>

There is evidence that one in 30 patients undergoing surgery with neuromuscular block but not receiving an anticholinergic drug at the end of surgery will show clinically relevant muscle weakness in the immediate postoperative period because of prolonged neuromuscular block (Table 3). There are two problems with this result. First, two trials reported residual muscle paralysis, and six did not. We do not know if residual paralysis occurred in these other trials but was not reported. Second, the result lacks statistical significance (i.e. 95% CI around the relative risk point estimate includes 1). However, residual paralysis was described only in patients who did not receive anticholinesterase drugs. Also, the result was based on data from systematically searched RCT, thus providing the strongest evidence currently available. The additional risk of residual muscle paralysis when antagonism of neuromuscular block is omitted is of the same magnitude as the additional risk of intraoperative awareness when nitrous oxide is omitted from general anaesthesia.

In one of the two relevant studies, neuromuscular block was achieved with a continuous infusion of mivacurium, a neuromuscular blocking agent with a fast recovery profile, and neuromuscular monitoring was used during operation. In the second report, a single bolus dose of vecuronium, an intermediate acting neuromuscular blocking agent, was used at induction. We have to assume that with the use of long-acting neuromuscular blocking agents (pancuronium, for instance), or with repeated doses of intermediate-acting neuromuscular blocking agents, or in the absence of adequate neuromuscular monitoring, the additional risk of residual paralysis when antagonism is omitted will be even higher.
Hypoxia, hypercapnia and pulmonary complications, including atelectasis and aspiration, are major health care problems and they may, theoretically, lead to death. The risk of death caused by pulmonary aspiration in the perioperative period was estimated to be very low. However, in a large RCT comparing different neuromuscular blocking agents in surgical patients using neuromuscular monitoring but not regular antagonism, almost 7% of patients developed postoperative pulmonary complications caused by residual muscle paralysis. Thus, unlike PONV, residual muscle paralysis in the postoperative period is not a minor adverse event and should be regarded as potentially very harmful.

The findings of this systematic review have implications for future research. First, no conclusions can be drawn on edrophonium. Second, there was some evidence of dose responsiveness with neostigmine. However, this may be regarded as hypothesis generating only, because the data were sparse. Thus we need large randomized trials testing the evidence that neostigmine has an impact on PONV, and that this effect is dose-dependent. Weight-adjusted doses of neostigmine should be tested to minimize variability. Finally, until the effect of anticholinesterase drugs on PONV can be based on strong evidence, these drugs should be adequately controlled and reported in RCT which investigate efficacy of antiemetic interventions. There is a possibility that anticholinesterase drugs may confound the results of antiemetic trials.

Acknowledgement
Dr Tramèr is supported by a PROSPER research grant from the Swiss National Science Foundation (Grant No. 3233–051939.97).

References
9 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4
11 McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Int Med 1997; 126: 712–20
21 Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994; 49 (Suppl.): 6–10
25 Chisakuta AM, Mirakkaruk RK. Anticholinergic prophylaxis does not prevent emesis following strabismus surgery in children. Paediatr Anaesth 1995; 5: 97–100
26 Kopman AF. Surrogate endpoints and neuromuscular recovery (editorial). Anesthesiology 1997; 87: 1029–31
29 Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of
the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 87: 1035–43

